Brian Ruffell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Recognitions
Brian Ruffell has a total of 411 co-authors. Here are the top co-authors by number of shared publications:
- Daiana P. Celias
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
35 shared publications - Ana Remírez
Centro de Investigación Médica Aplicada 3 Pamplona
34 shared publications - Ana Rouzaut
Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain
34 shared publications - Beatriz Tavira
Division of Pediatrics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden
34 shared publications - Carlos Eduardo de Andrea
Navarra Institute for Health Research (IdISNA), Pamplona, Spain
34 shared publications - Cristina Sainz
Navarre Institute of Health Research 4 Pamplona
34 shared publications
Latest Publications
- 5 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
KRAS-G12C Inhibition–Induced Enrichment of MHC-Ihigh Immune-Active Tumor Cells Directs Immune-Effector TME Development to Augment Therapeutic Efficacy
Inhibition of KRASG12C (G12Ci) has shown promising clinical activity in several cancers; however, emergence of resistance is a major limitation to long-term benefit. It remains unknown how G12Ci affects the tumor-immune microenvironment and its association with resistance. We investigated the immune-modulatory impact of the G12Ci sotorasib in KrasG12C/Trp53−/− lung and colon carcinoma models. Single-cell RNA sequencing of tumors in both models demonstrated sotorasib-induced loss of proliferative tumor cells and the enrichment of immune-active tumor cells with elevated NF-κB and IFN signaling and elevated MHC-I expression. These changes led to an increased proportion of effector T cells and MHC-IIhigh macrophages in the tumors and a reduced proportion of regulatory myeloid cells. Furthermore, sotorasib-resistant tumors exhibited a marked reduction of MHC-Ihigh immune-active tumor cells and immune cell type changes. Enrichment of immune-active tumor cells was associated directly with sotorasib-induced activation of NF-κB and STAT1, leading to heightened responsiveness to inflammatory cytokines and upregulation of MHC-I and chemokine expression. These findings indicate that modulation of immune-active tumor cell populations is a key mechanism associated with G12Ci therapeutic efficacy and the development of resistance. Watch first author Mohammed L. Ibrahim, B. Pharm, PhD, from California Northstate University College of Medicine describe this article: https://vimeo.com/showcase/12408339?video=1227805308.
- 5 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
KRAS-G12C Inhibition–Induced Enrichment of MHC-Ihigh Immune-Active Tumor Cells Directs Immune-Effector TME Development to Augment Therapeutic Efficacy
Inhibition of KRASG12C (G12Ci) has shown promising clinical activity in several cancers; however, emergence of resistance is a major limitation to long-term benefit. It remains unknown how G12Ci affects the tumor-immune microenvironment and its association with resistance. We investigated the immune-modulatory impact of the G12Ci sotorasib in KrasG12C/Trp53−/− lung and colon carcinoma models. Single-cell RNA sequencing of tumors in both models demonstrated sotorasib-induced loss of proliferative tumor cells and the enrichment of immune-active tumor cells with elevated NF-κB and IFN signaling and elevated MHC-I expression. These changes led to an increased proportion of effector T cells and MHC-IIhigh macrophages in the tumors and a reduced proportion of regulatory myeloid cells. Furthermore, sotorasib-resistant tumors exhibited a marked reduction of MHC-Ihigh immune-active tumor cells and immune cell type changes. Enrichment of immune-active tumor cells was associated directly with sotorasib-induced activation of NF-κB and STAT1, leading to heightened responsiveness to inflammatory cytokines and upregulation of MHC-I and chemokine expression. These findings indicate that modulation of immune-active tumor cell populations is a key mechanism associated with G12Ci therapeutic efficacy and the development of resistance. Watch first author Mohammed L. Ibrahim, B. Pharm, PhD, from California Northstate University College of Medicine describe this article: https://vimeo.com/showcase/12408339?video=1227805308.